Voyager Therapeutics(US:VYGR)2026-03-09 20:02Financial Performance - The company reported a net income of $132.3 million for the year ended December 31, 2023, but has a history of significant losses, with net losses of $119.7 million and $65.0 million for the years ended December 31, 2025 and 2024, respectively [687]. - The company has an accumulated deficit of $445.9 million as of December 31, 2025, and expects to continue incurring significant expenses and operating losses in the foreseeable future [687]. - The net loss for 2025 was $119.7 million, compared to a net loss of $65.0 million in 2024, representing an increase in loss of 84.3% [708]. - The company reported a loss before income taxes of $119.6 million in 2025, compared to a loss of $64.3 million in 2024, an increase of 85.9% [708]. Revenue and Collaboration - The company recognized $30.5 million in collaboration revenue from the 2023 Neurocrine Collaboration Agreement for the year ended December 31, 2025, along with additional revenues from other collaboration agreements totaling $40.4 million [690]. - Collaboration revenue decreased to $40.4 million in 2025 from $80.0 million in 2024, a decline of 50% [709]. - Collaboration revenue for 2024 was $80.0 million, down from $250.0 million in 2023, a decrease of 68% [715]. - The company has potential to earn up to $6.8 billion in milestone payments across its partnered portfolio, including $2.4 billion in potential development milestone payments [683]. - The company has entered into multiple collaboration and licensing agreements, delivering over $500 million in non-dilutive funding to date [683]. Research and Development - Research and development expenses are expected to decrease in the near term due to portfolio prioritization and alignment of operating expenditures with current capital resources [693]. - Research and development expenses rose to $134.7 million in 2025, up from $127.4 million in 2024, an increase of 5.7% [710]. - Research and development expenses increased significantly by $35.2 million from $92.2 million in 2023 to $127.4 million in 2024, an increase of 38.2% [716]. - Total research and development expenses increased to $127.4 million in 2024 from $92.2 million in 2023, representing a change of $35.2 million or 38.2% [717]. - Internal research and development expenses rose to $38.4 million in 2024 from $27.9 million in 2023, an increase of $10.6 million or 38.1% [717]. - The company expects to continue incurring research and development expenses as clinical trials progress and marketing approvals are sought [734]. - The company has paused investment in its apolipoprotein E gene therapy program to prioritize other programs, despite demonstrating dose-dependent APOE4 protein reduction in murine studies [678]. - The company is advancing its proprietary pipeline, including VY1706, which showed a 50% to 73% reduction in tau mRNA levels in a non-human primate study, and VY7523, which reduced tau spread by approximately 70% in preclinical studies [677]. - The company initiated a Phase 1 multiple ascending dose clinical trial of VY7523 in early AD patients in February 2025, with initial tau PET imaging data expected in the second half of 2026 [677]. - The company expects to submit an investigational new drug application for VY1706 in the second quarter of 2026 and initiate a clinical trial in the second half of 2026 [677]. Operating Expenses - Total operating expenses increased to $172.2 million in 2025 from $163.3 million in 2024, an increase of 5.5% [708]. - General and administrative expenses increased to $37.5 million in 2025 from $35.9 million in 2024, a rise of 4.5% [711]. - Other income, net decreased to $12.3 million in 2025 from $19.0 million in 2024, a decline of 35.4% [712]. - Net cash used in operating activities was $15.3 million in 2024, driven by a net loss of $65.0 million and a decrease in deferred revenue of $44.8 million [724]. - Net cash used in investing activities was $94.9 million in 2024, primarily due to $465.7 million for purchases of marketable securities [727]. Cash and Financing - Cash, cash equivalents, and marketable securities totaled $201.7 million as of December 31, 2025, expected to meet operating expenses into 2028 [735]. - Net cash provided by financing activities was $114.0 million in 2024, mainly from $93.5 million in net proceeds from a public offering of common stock and warrants [732]. Market Risks - The company is primarily exposed to market risk related to interest rate sensitivity, particularly due to investments in money market funds and marketable securities [746]. - An immediate 100 basis point change in interest rates is not expected to have a material effect on the fair market value of the company's investment portfolio [746]. - The company is not currently exposed to market risk from foreign currency exchange rates but may face such risks in future contracts with vendors in Asia and Europe [747]. - Inflation has not had a material effect on the company's business, financial condition, or results of operations for the year ended December 31, 2025 [747].